143 related articles for article (PubMed ID: 32804837)
1. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study.
Li H; Xia XJ; Zhang LF; Chi JS; Liu P; Wu H; Xie XR; Tian DL; Kun KX; Gong RJ; Liu XM; Xu CX
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):194-200. PubMed ID: 32804837
[TBL] [Abstract][Full Text] [Related]
2. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Liao XM; Nong GH; Chen MZ; Huang XP; Cong YY; Huang YY; Wu BH; Wei JQ
World J Gastroenterol; 2015 May; 21(20):6310-6. PubMed ID: 26034367
[TBL] [Abstract][Full Text] [Related]
3. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
4. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
5. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
6. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
Arab J Gastroenterol; 2021 Mar; 22(1):47-51. PubMed ID: 33551347
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
[TBL] [Abstract][Full Text] [Related]
8. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
11. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
13. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
14. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
15. Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Xie Y; Hu Y; Zhu Y; Wang H; Wang QZ; Li YQ; Wang JB; Zhang ZY; Zhang DK; Liu XW; Lu NH
Helicobacter; 2023 Jun; 28(3):e12978. PubMed ID: 37002653
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
[TBL] [Abstract][Full Text] [Related]
17. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
19. [A multicenter randomized controlled study of bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang in the treatment of patients newly diagnosed with
Ma PP; Meng LN; Wang MT; Jin HF; Fan YH; Zha AS; Huo XH; Chen DF; Cao ZQ; Tang XF; Yang P; Shi ZH; Li TW; Meng J; Gan C; Chen GX; Sha WH; Du Q; Li Y; Lyu B
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(26):2060-2065. PubMed ID: 34275239
[No Abstract] [Full Text] [Related]
20. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
